Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Buparlisib is a brain penetrable pan-PI3K inhibitor.

de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O.

Sci Rep. 2018 Jul 17;8(1):10784. doi: 10.1038/s41598-018-29062-w.

2.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O.

Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28.

3.

Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8.

Berenguer J, Lagerweij T, Zhao XW, Dusoswa S, van der Stoop P, Westerman B, de Gooijer MC, Zoetemelk M, Zomer A, Crommentuijn MHW, Wedekind LE, López-López À, Giovanazzi A, Bruch-Oms M, van der Meulen-Muileman IH, Reijmers RM, van Kuppevelt TH, García-Vallejo JJ, van Kooyk Y, Tannous BA, Wesseling P, Koppers-Lalic D, Vandertop WP, Noske DP, van Beusechem VW, van Rheenen J, Pegtel DM, van Tellingen O, Wurdinger T.

J Extracell Vesicles. 2018 Mar 13;7(1):1446660. doi: 10.1080/20013078.2018.1446660. eCollection 2018.

4.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O.

Invest New Drugs. 2018 Jun;36(3):380-387. doi: 10.1007/s10637-017-0539-8. Epub 2017 Nov 17.

PMID:
29147815
5.

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer MC, Wakimoto H, Barazas M, Tannous M, Chi AS, Noske DP, Wesseling P, Wurdinger T, Batchelor TT, Tannous BA.

Neuro Oncol. 2018 Apr 9;20(5):642-654. doi: 10.1093/neuonc/nox198.

PMID:
29099956
6.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O.

Int J Cancer. 2018 Jan 15;142(2):381-391. doi: 10.1002/ijc.31052. Epub 2017 Oct 4.

PMID:
28921565
7.

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Pencheva N, de Gooijer MC, Vis DJ, Wessels LFA, Würdinger T, van Tellingen O, Bernards R.

Cell Rep. 2017 Jul 5;20(1):48-60. doi: 10.1016/j.celrep.2017.06.036.

8.

The G2 checkpoint-a node-based molecular switch.

de Gooijer MC, van den Top A, Bockaj I, Beijnen JH, Würdinger T, van Tellingen O.

FEBS Open Bio. 2017 Mar 4;7(4):439-455. doi: 10.1002/2211-5463.12206. eCollection 2017 Apr.

9.

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.

Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, van Tellingen O.

Clin Cancer Res. 2017 Mar 1;23(5):1286-1298. doi: 10.1158/1078-0432.CCR-16-1276. Epub 2016 Aug 23.

10.

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LC, Beijnen JH, van Tellingen O.

Invest New Drugs. 2015 Oct;33(5):1012-9. doi: 10.1007/s10637-015-0266-y. Epub 2015 Jul 1.

PMID:
26123925
11.

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

Zhang P, de Gooijer MC, Buil LC, Beijnen JH, Li G, van Tellingen O.

Int J Cancer. 2015 Oct 15;137(8):2007-18. doi: 10.1002/ijc.29566. Epub 2015 Apr 24.

12.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
13.

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Würdinger T, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2014 May 15;20(10):2703-13. doi: 10.1158/1078-0432.CCR-14-0084. Epub 2014 Mar 19.

14.

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O.

CNS Oncol. 2013 May;2(3):271-88. doi: 10.2217/cns.13.15. Review.

PMID:
25054467
15.

Directed molecular evolution reveals Gaussia luciferase variants with enhanced light output stability.

Degeling MH, Bovenberg MS, Lewandrowski GK, de Gooijer MC, Vleggeert-Lankamp CL, Tannous M, Maguire CA, Tannous BA.

Anal Chem. 2013 Mar 5;85(5):3006-12. doi: 10.1021/ac4003134. Epub 2013 Feb 20.

16.

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15;901:9-17. doi: 10.1016/j.jchromb.2012.05.033. Epub 2012 Jun 8.

PMID:
22727754

Supplemental Content

Loading ...
Support Center